Glioblastoma, a highly aggressive and malignant brain tumor classified as WHO grade IV, continues to pose a significant challenge despite the current standard of care. The current treatment approach involves several strategies, including maximal safe resection and radiotherapy combined with temozolomide (TMZ). The outlook for individuals with glioblastoma remains bleak. However, there is a ray of hope in the form of immunotherapy, a method that harnesses the power of the immune system to seek out and destroy cancer cells. The remarkable achievements of immunotherapy in treating different types of solid tumors, including melanoma, non-small cell lung cancer, and non-Hodgkin’s lymphoma, have catalyzed the creation of a range of immunotherapeutic approaches for glioblastoma. These strategies encompass methods like immune checkpoint blockade, T-cell transplantation, vaccination, and viral approaches. However, the outcomes of phase III clinical trials have often fallen short of expectations, largely due to challenges such as the presence of the blood-brain barrier, tumor heterogeneity, an immunosuppressive tumor microenvironment, and a scarcity of glioblastoma-specific targets. Recently, promising results have emerged from new combination strategies in both preclinical and clinical settings. In this summary, we provide an overview of the preclinical evidence supporting these combination strategies in the management of glioblastoma.